Septerna, Inc.
NASDAQ:SEPNBiotechnology
-$0.73 today
- Market cap
- $1.88B
- Beta
- 2.38
- P/E (TTM)
- -43.6
- EPS (TTM)
- -$0.81
Volume 0.30M
Average 0.32M
SEPN Other Income / Expenses
Net non-operating gains and losses, such as investment results, currency effects, and one-off items.
Septerna, Inc.NASDAQ: SEPN
Other Income / Expenses · Q3 FY2026 · quarter ended Sep 2026
Other income / expenses dips below year-ago levels
Q3 FY2026 other income / expenses of $5.26M fell 5.4% year over year, behind the +12.8% change in trailing-twelve-month other income / expenses. Sequentially, it rose 10.2% from the prior quarter.
Context
- Other income / expenses amounted to 69.5% of revenue in FY2025, down 723.7 pp from a year earlier.
- Other income / expenses increased in 2 of the last 2 fiscal years.
- FY2025 was the highest annual figure in the 3 fiscal years shown.
What to watch
Whether quarterly growth recovers from -5.4% toward the trailing-twelve-month pace of +12.8%.
Sources:Income StatementText generated from reported figures; not investment advice.
Other Income / Expenses history
USD · from the income statement
- Latest · FY2025
- 31.93M USD
- Year-over-year change
- +274.5%
- 2-year CAGR
- +237.9%
| Period | Period end | Other Income / Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 31.93M | +274.5% |
| FY2024 | 2024-12-31 | 8.53M | +205.0% |
| FY2023 | 2023-12-31 | 2.8M | — |
Other Income / Expenses vs competitors
How SEPN compares with its peers on the latest reported figures
- SEPN's LTM Sep 2026 other income / expenses of $20.33M is the 3rd highest of the 7 companies compared; the peer median is $13.37M.
- Its year-over-year change of +12.8% is the 4th highest of 6, against a peer median of +46.9%.
- Other income / expenses amounts to 21.1% of revenue for SEPN, versus a peer median of 31.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $43.71M | +6.2% | +388.5% | — | |
| LTM Mar 2026 | $21.62M | +427.9% | +121.1% | — | |
SEPNSepterna, Inc. | LTM Sep 2026 | $20.33M | +12.8% | — | 21.1% |
MBXMBX Biosciences, Inc. Common Stock | LTM Sep 2026 | $15.24M | +46.9% | — | — |
| LTM Mar 2026 | $11.51M | +295.2% | — | 57.5% | |
KLRAKailera Therapeutics, Inc. | FY2025 | $9.39M | — | — | — |
| LTM Mar 2026 | $2.31M | +7.4% | — | 6.3% | |
| Peer median (excluding SEPN) | $13.37M | +46.9% | +254.8% | 31.9% | |
Competitors are the stored peer set for SEPN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|
| Revenue | 151K | 1.08M | 45.95M |
| Cost of Revenue | 0 | 0 | 0 |
| Gross Profit | 151K | 1.08M | 45.95M |
| Gross Margin | 100.0% | 100.0% | 100.0% |
| Research & Development | 35.98M | 65.34M | 97.58M |
| Selling, General & Admin | 9.72M | 16.56M | 29.16M |
| Operating Expenses | (1.92M) | 81.9M | 126.75M |
| Depreciation & Amortization | 848K | 1.4M | 1.6M |
| EBITDA | (44.7M) | (70.9M) | (47.26M) |
| EBITDA Margin | -29604.0% | -6594.9% | -102.9% |
| Operating Income | 2.08M | (80.82M) | (80.8M) |
| Operating Margin | 1374.2% | -7518.4% | -175.8% |
| Interest Income | 2.79M | 8.62M | 19.53M |
| Interest Expense | 0 | 0 | 0 |
| Other Income / Expenses | 2.8M | 8.53M | 31.93M |
| Income Before Tax | 4.87M | (72.3M) | (48.87M) |
| Pre-Tax Margin | 3225.8% | -6725.2% | -106.3% |
| Income Tax Expense | 691K | (498K) | 12K |
| Net Income | 4.18M | (71.8M) | (48.88M) |
| Net Margin | 2768.2% | -6678.9% | -106.4% |
| EPS (Basic) | 0.03 | (1.93) | (1.10) |
| EPS (Diluted) | 0.03 | (1.93) | (1.10) |
| Weighted Avg Shares | 19.5M | 37.19M | 44.26M |
| Weighted Avg Shares (Diluted) | 19.5M | 37.19M | 44.26M |
Septerna, Inc.
NASDAQ:SEPN
Intrinsic Alpha fair value
Locked
Current Price
$39.45
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.